TriOar is a biotech company focusing on developing next-generation antibody-based therapeutics with novel platform technologies.

Overview

TriOar's platform technologies are expected to improve
a therapeutic index of anti-cancer agents.

TriOar's novel platform technologies are expected to improve a therapeutic index by reducing toxicity and increasing efficacy simultaneously.

TriOar's novel platform technologies can be applied to various modalities including Antibody-Drug Conjugates and Immuno-Oncology.

  • New platforms for
    antibody-based
    therapeutics
  • Novel linker-toxin
    system
  • Antibody
    drug conjugates
    (ADCs)
  • Immuno-Oncology
    (IO)